Sec Form 4 Filing - Maduck Sean @ CORCEPT THERAPEUTICS INC - 2021-09-01

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Maduck Sean 2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [ CORT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Commercial Officer (Last) (First) (Middle) C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE 3. Date of Earliest Transaction (MM/DD/YY) 09/01/2021 (Street) MENLO PARK, CA94025 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 09/01/2021 M( 1 ) 25,000 A $ 3.29 65,024 D Common Stock 09/01/2021 S( 1 ) 25,000 D $ 21.3972 ( 2 ) 40,024 D Common Stock 10,000 I See Footnote ( 3 ) Common Stock 10,000 I See Footnote ( 4 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form o f Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 3.29 09/01/2021 M( 1 ) 25,000 ( 5 ) 02/18/2025 Common Stock 25,000 $ 0 147,602 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Maduck Sean C/O CORCEPT THERAPEUTICS INCORPORATED 149 COMMONWEALTH DRIVE MENLO PARK, CA94025 Chief Commercial Officer Signatures /s/ Joseph Douglas Lyon, Attorney-in-Fact for Sean Nicholas 09/03/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. ( 2 )Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $21.38 to $21.445 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. ( 3 )Represents the shares held by Duckhill Capital, LLC of which the reporting person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. ( 4 )Represents the shares held by Sean and Molly Maduck Living Trust of which the reporting person is a co-trustee. ( 5 )Fully exercisable.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.